The team tested the efficacy of visugromab, a neutralizing anti-GDF-15 antibody, in combination with the anti-PD-1 antibody nivolumab. The Phase 1/2a clinical trial enrolled patients with advanced ...

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.

CatalYm publishes data in Nature Communications describing gdf-15 as a central factor of anti-PD-1 resistance Trophic Communications Journal Nature Communications Funder Interdisciplinary Centre ...

CatalYm is developing visugromab, a first-in-class anti-GDF-15 antibody, in solid tumors and other indications. In its first-in-human Phase 1/2a study, visugromab demonstrated durable anti-tumor ...